Abstract
Of the numerous strategies that have been tested to slow the clearance of injected protein drugs from the body and circulation (1), fusion to albumin offers several advantages. Albumin is the most abundant protein in mammalian plasma and one of the longest lived. It lacks posttranslational modifications, with the exception of extensive disulfide bonding (2). If albumin can be fused in-frame with a therapeutic protein as a single-chain polypeptide, the novel protein may acquire the slow clearance profile of albumin, while retaining the activity important for clinical use. This acquisition derives primarily from an increase in the molecular volume of the therapeutic protein, such that it is no longer subject to loss via the kidneys. This approach has the potential to provide a more consistent and less heterogeneous product than one obtained, for instance, by chemical modification with polyethylene glycol. Whereas others have used Kluveromyces (3,4) and Saccharomyces (5) yeast species to produce human serum albumin (HSA) fusion proteins, we have used the methylotropic yeast, Pichia pastoris, to produce rabbit serum albumin (RSA) fusion proteins. This system is particularly well suited for albumin production (6). This chapter summarizes our experience gained in expressing hirudin (7), barbourin (8), and reiterated RSA fusion proteins (9) in this system.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sheffield, W. P. (2001) Modification of clearance of therapeutic and potentially therapeutic proteins. Curr. Drug Targets Cardiovasc. Haematol. Disord. 1, 1–22.
Peters, T. (1985) Serum albumin. Adv. Prot. Chem. 37, 161–245.
Yeh, P., Landais, D., Lemaitre, M., Maury, I., Crenne, J. Y., Becquart, J., et al. (1992) Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc. Natl. Acad. Sci. USA 89, 1904–1908.
Lu, H., Yeh, P., Guitton, J. D., Mabilat, C., Desanlis, F., Maury, I., et al. (1994) Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett. 356, 56–59.
Nomura, N., Matsubara, N., Horinouchi, S., and Beppu, T. (1995) Secretion by Saccharomyces cerevisiae of human apolipoprotein E as a fusion to serum albumin. Biosci. Biotechnol. Biochem. 59, 532–534.
Kobayashi, K., Nakamura, N., Sumi, A., Ohmura, T., and Yokoyama, K. (1998) The development of recombinant human serum albumin. Ther. Apher. 2, 257–262.
Sheffield, W. P., Smith, I. J., Syed, S. S., and Bhakta, V. (2001) Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris. Blood Coagul. Fibrinolysis 12, 433–443.
Marques, J. A., George, J. K., Smith, I. J., Bhakta, V., and Sheffield, W. P. (2001) A barbourin albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. Thromb. Haemost. 86, 902–908.
McCurdy, T. R., Gataiance, S., Eltringham-Smith, L. J., and Sheffield, W. P. (2004) A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than wild-type and mutant C34A albumin. J. Lab. Clin. Med. 143, 115–124.
Cregg, J. M., Vedvick, T. S., and Raschke, W. C. (1993) Recent advances in the expression of foreign genes in Pichia pastoris. Biotechnology (NY) 11, 905–910.
Higgins, D. R. and Cregg, J. M., eds. Pichia Protocols. Humana, Totowa, NJ, 1998.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Sheffield, W.P., McCurdy, T.R., Bhakta, V. (2005). Fusion to Albumin as a Means to Slow the Clearance of Small Therapeutic Proteins Using the Pichia pastoris Expression System. In: Smales, C.M., James, D.C. (eds) Therapeutic Proteins. Methods in Molecular Biology™, vol 308. Humana Press. https://doi.org/10.1385/1-59259-922-2:145
Download citation
DOI: https://doi.org/10.1385/1-59259-922-2:145
Publisher Name: Humana Press
Print ISBN: 978-1-58829-390-9
Online ISBN: 978-1-59259-922-6
eBook Packages: Springer Protocols